| 1.48 -0.15 (-9.2%) | 08-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.53 |
1-year : | 3.03 |
| Resists | First : | 2.16 |
Second : | 2.59 |
| Pivot price | 2.19 |
|||
| Supports | First : | 1.47 |
Second : | 1.22 |
| MAs | MA(5) : | 1.98 |
MA(20) : | 2.21 |
| MA(100) : | 2.03 |
MA(250) : | 2.4 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 17.1 |
D(3) : | 31.5 |
| RSI | RSI(14): 28.3 |
|||
| 52-week | High : | 3.61 | Low : | 1.26 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BTMD ] has closed below the lower bollinger band by 15.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ BTMD ] is to continue within current trading range. It is unclear right now based on current values. 73.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.92 - 1.94 | 1.94 - 1.94 |
| Low: | 1.53 - 1.54 | 1.54 - 1.55 |
| Close: | 1.61 - 1.63 | 1.63 - 1.65 |
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
Fri, 07 Aug 2026
biote Corp (NASDAQ: BTMD) swings to Q2 2026 loss as costs rise - Stock Titan
Thu, 06 Aug 2026
Biote Corp (BTMD) (Q2 2026) Earnings Call Highlights: Navigating Recall Challenges and ... - Yahoo Finance
Wed, 05 Aug 2026
biote Corp. (BTMD) Reports Break-Even Earnings for Q2 - Yahoo Finance
Wed, 05 Aug 2026
biote Corp. (BTMD) Releases Q2 2026 Earnings: Revenue Declines and EPS Miss - Quiver Quantitative
Wed, 05 Aug 2026
Biote Corp (NASDAQ: BTMD) swings to Q2 2026 loss as recall hits sales - Stock Titan
Tue, 04 Aug 2026
Earnings To Watch: Biote Corp (BTMD) Q2 2026 -- GF Value Sees 39% Upside - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 30 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 10.3 (%) |
| Held by Institutions | 67 (%) |
| Shares Short | 579 (K) |
| Shares Short P.Month | 1,290 (K) |
| EPS | 0.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.88 |
| Profit Margin | 8.2 % |
| Operating Margin | 9.7 % |
| Return on Assets (ttm) | 17.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -8.4 % |
| Gross Profit (p.s.) | 4.34 |
| Sales Per Share | 6.2 |
| EBITDA (p.s.) | 1.08 |
| Qtrly Earnings Growth | -83.9 % |
| Operating Cash Flow | 33 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | 3.44 |
| PEG Ratio | 0 |
| Price to Book value | -0.8 |
| Price to Sales | 0.23 |
| Price to Cash Flow | 1.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|